Gimv (EBR:GIMB) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

BRIEF

published on 11/27/2025 at 07:35, 7 days 20 hours ago

Gimv and CNP Partner to Propel Equine Care Group's Global Growth

Global Expansion Gimv Equine Care Group CNP Equine Healthcare
REGULATED PRESS RELEASE

published on 11/27/2025 at 07:30, 7 days 21 hours ago

Gimv joins forces with CNP to accelerate the global expansion of Equine Care Group
Gimv partners with CNP to boost Equine Care Group's global expansion, aiming to lead in equine medicine innovation and excellence with minority stake acquisition

Global Expansion Gimv Equine Care Group CNP Equine Medicine
REGULATED PRESS RELEASE

published on 11/20/2025 at 07:00, 14 days 21 hours ago

Solid growth performance in the first half of FY 2025
BRIEF

published on 11/05/2025 at 07:35, 29 days 20 hours ago

Gimv Invests in Quality Guard for European Food Safety Compliance

SaaS Platform European Expansion Gimv Investment Quality Guard Food Safety Compliance
REGULATED PRESS RELEASE

published on 11/05/2025 at 07:30, 29 days 21 hours ago

Gimv partners with Quality Guard to establish a leading software platform for food safety compliance across Europe
Gimv partners with Quality Guard to establish a leading software platform for food safety compliance across Europe. Quality Guard offers digital tools for HACCP, food safety, and allergen management, supported by IoT-enabled hardware

Gimv SaaS Platform European Footprint Quality Guard Food Safety Compliance
BRIEF

published on 10/22/2025 at 07:35, 1 month 13 days ago

Gimv Sells Stake in ImCheck Therapeutics to Ipsen

AML Treatment ImCheck Therapeutics Ipsen Acquisition Gimv Stake Sale ICT01 Program
REGULATED PRESS RELEASE

published on 10/22/2025 at 07:30, 1 month 13 days ago

Gimv Life Sciences realizes successful exit with the sale of its stake in Imcheck Therapeutics to Ipsen
Gimv Life Sciences successfully exits ImCheck Therapeutics with sale to Ipsen, creating value for shareholders and advancing medical innovation in oncology

Oncology Medical Innovation Ipsen ImCheck Therapeutics Gimv Life Sciences
BRIEF

published on 09/26/2025 at 07:35, 2 months 8 days ago

Spineart Secures CHF 25 Million to Boost Global Growth

Global Expansion Gimv EGS Beteiligungen Spineart CHF 25 Million
REGULATED PRESS RELEASE

published on 09/26/2025 at 07:30, 2 months 8 days ago

Gimv and EGS Beteiligungen reinforce strategic support for Spineart with CHF 25 million capital increase to accelerate global growth
Spineart secures CHF 25 million investment from Gimv and EGS Beteiligungen to accelerate global expansion in advanced spine surgery solutions

Gimv Investment Spine Surgery EGS Beteiligungen Spineart
BRIEF

published on 09/02/2025 at 07:05, 3 months 2 days ago

Gimv Reports Strong Start to Fiscal Year with Robust Investment Activity

Growth Strategy Financial Performance Private Equity Investment Portfolio

Accesswire

Published on 12/05/2025 at 02:35, 1 hour 59 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 4 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 3 hours 34 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 29 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 34 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 3 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 43 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 8 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 19 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 23 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 10 hours 34 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 49 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 49 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 33 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE